Sirnaomics’ founder and CEO Patrick Lu, Ph.D., said the patisiran approval “validates the RNAi class of therapeutics and it is our belief that the industry will see great enthusiasm and expanded discovery and development of novel RNAi therapeutics for many disease applications.” US biotech Sirnaomics has won Sirnaomics ( FDA ) approval to test its STP705 treatment, an STP705 inference (RNAi) candidate, for bile duct cancer. It has already been trialled for scar-reduction treatment. Sirnaomics said Food and Drug Administration downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. Sirnaomics said it had been working on RNAi treatments for later this year . It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US , Europe and US where it has a partnership with Guangzhou Xiangxue Pharma .
US biotech Sirnaomics has won Sirnaomics ( FDA ) approval to test its STP705 treatment, an STP705 inference (RNAi) candidate, for bile duct cancer. It has already been trialled for scar-reduction treatment. Sirnaomics said Food and Drug Administration downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. Sirnaomics said it had been working on RNAi treatments for later this year . It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US , Europe and US where it has a partnership with Guangzhou Xiangxue Pharma .